TY - JOUR
T1 - Involvement of Caveolin-1-mediated transcytosis in the intratumoral accumulation of liposomes
AU - Sakurai, Yu
AU - Kato, Akari
AU - Harashima, Hideyoshi
N1 - Funding Information:
The authors wish to thank Dr. Milton S Feather for appropriately modifying the manuscript. This study was supported, in part, by Ministry of Health, Labour and Welfare , by Ministry of Education, Culture, Sports, Science and Technology , by Japan Society for the Promotion of Science KAKENHI (Grant No. 18K18351 ), by the Ichiro-Kanehara foundation and by The Mochida Memorial Foundation for Medical and Pharmaceutical Research .
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/4/30
Y1 - 2020/4/30
N2 - For achieving efficient cancer treatment, it is important to elucidate the mechanism responsible for the accumulation of nanoparticles in tumor tissue. Recent studies suggest that nanoparticles are not delivered merely through gaps between tumor endothelial cells. We previously reported that the maturation of the vascular structure by the vascular endothelial cell growth factor receptor 2 (VEGFR2) using a previously developed siRNA delivery technology (RGD-MEND) significantly enhanced the accumulation of nanoparticles in types of cancers that area vessel-rich (renal cell carcinoma). This result was completely inconsistent with the generally accepted theory of the enhanced permeability and retention (EPR) effect. We hypothesized that a caveolin-1 (Cav1)-mediated transcellular route would be involved with the penetration of nanoparticles into tumor vasculature. To reveal the exact mechanism responsible for this enhancement, we observed the delivery of long-circulating liposomes (LPs) after Cav1 was co-suppressed by RGD-MEND with VEGFR2. The enhanced delivery of LPs by siRNA against VEGFR2 (siVEGFR2) was accompanied by the elevated expression of the Cav1 protein. In addition, Cav1 knockdown by siRNA against Cav1 (siCav1) canceled the enhanced delivery of LPs by siVEGFR2. The injection of siCav1 had no effect on the formation of alpha smooth muscle actin or vascular endothelial cell adhesion molecules. These results suggest that a Cav1-induced transcellular route and not a paracellular route, at least partially, contributes to the accumulation of nanoparticles in tumors.
AB - For achieving efficient cancer treatment, it is important to elucidate the mechanism responsible for the accumulation of nanoparticles in tumor tissue. Recent studies suggest that nanoparticles are not delivered merely through gaps between tumor endothelial cells. We previously reported that the maturation of the vascular structure by the vascular endothelial cell growth factor receptor 2 (VEGFR2) using a previously developed siRNA delivery technology (RGD-MEND) significantly enhanced the accumulation of nanoparticles in types of cancers that area vessel-rich (renal cell carcinoma). This result was completely inconsistent with the generally accepted theory of the enhanced permeability and retention (EPR) effect. We hypothesized that a caveolin-1 (Cav1)-mediated transcellular route would be involved with the penetration of nanoparticles into tumor vasculature. To reveal the exact mechanism responsible for this enhancement, we observed the delivery of long-circulating liposomes (LPs) after Cav1 was co-suppressed by RGD-MEND with VEGFR2. The enhanced delivery of LPs by siRNA against VEGFR2 (siVEGFR2) was accompanied by the elevated expression of the Cav1 protein. In addition, Cav1 knockdown by siRNA against Cav1 (siCav1) canceled the enhanced delivery of LPs by siVEGFR2. The injection of siCav1 had no effect on the formation of alpha smooth muscle actin or vascular endothelial cell adhesion molecules. These results suggest that a Cav1-induced transcellular route and not a paracellular route, at least partially, contributes to the accumulation of nanoparticles in tumors.
KW - Cancer
KW - EPR effect
KW - Nanoparticle
KW - Transcellular
KW - Vasculature
UR - http://www.scopus.com/inward/record.url?scp=85079873496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079873496&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2020.02.086
DO - 10.1016/j.bbrc.2020.02.086
M3 - Article
C2 - 32087973
AN - SCOPUS:85079873496
SN - 0006-291X
VL - 525
SP - 313
EP - 318
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 2
ER -